Jounce Therapeutics' stock fell to a 52-week low Monday as shaky efficacy data from a Phase 1/2 trial of the biotech's lead drug weighed on the company's share price.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,